Review of teriflunomide and its potential in the treatment of multiple sclerosis

Clemens Warnke, Gerd Meyer Zu Hörste, Hans Peter Hartung, Olaf Stüve, Bernd C. Kieseier

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalNeuropsychiatric Disease and Treatment
Volume5
Issue number1
StatePublished - 2009

Fingerprint

Multiple Sclerosis
Immunosuppressive Agents
Progressive Multifocal Leukoencephalopathy
Phase III Clinical Trials
Therapeutics
Autoimmunity
Pharmaceutical Preparations
Rheumatoid Arthritis
Safety
teriflunomide

Keywords

  • Immunosuppressant
  • Multiple sclerosis
  • Oral drugs
  • Teriflunomide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Warnke, C., Zu Hörste, G. M., Hartung, H. P., Stüve, O., & Kieseier, B. C. (2009). Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatric Disease and Treatment, 5(1), 333-340.

Review of teriflunomide and its potential in the treatment of multiple sclerosis. / Warnke, Clemens; Zu Hörste, Gerd Meyer; Hartung, Hans Peter; Stüve, Olaf; Kieseier, Bernd C.

In: Neuropsychiatric Disease and Treatment, Vol. 5, No. 1, 2009, p. 333-340.

Research output: Contribution to journalArticle

Warnke, C, Zu Hörste, GM, Hartung, HP, Stüve, O & Kieseier, BC 2009, 'Review of teriflunomide and its potential in the treatment of multiple sclerosis', Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 333-340.
Warnke, Clemens ; Zu Hörste, Gerd Meyer ; Hartung, Hans Peter ; Stüve, Olaf ; Kieseier, Bernd C. / Review of teriflunomide and its potential in the treatment of multiple sclerosis. In: Neuropsychiatric Disease and Treatment. 2009 ; Vol. 5, No. 1. pp. 333-340.
@article{64b38abdb0f24bbc8674c4d36b6f2aba,
title = "Review of teriflunomide and its potential in the treatment of multiple sclerosis",
abstract = "In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.",
keywords = "Immunosuppressant, Multiple sclerosis, Oral drugs, Teriflunomide",
author = "Clemens Warnke and {Zu H{\"o}rste}, {Gerd Meyer} and Hartung, {Hans Peter} and Olaf St{\"u}ve and Kieseier, {Bernd C.}",
year = "2009",
language = "English (US)",
volume = "5",
pages = "333--340",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Review of teriflunomide and its potential in the treatment of multiple sclerosis

AU - Warnke, Clemens

AU - Zu Hörste, Gerd Meyer

AU - Hartung, Hans Peter

AU - Stüve, Olaf

AU - Kieseier, Bernd C.

PY - 2009

Y1 - 2009

N2 - In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.

AB - In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.

KW - Immunosuppressant

KW - Multiple sclerosis

KW - Oral drugs

KW - Teriflunomide

UR - http://www.scopus.com/inward/record.url?scp=70449717876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449717876&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 333

EP - 340

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 1

ER -